Melanie K. Kuester

How might requiring Part D coverage for anti-obesity medications affect Medicare program costs?

As drug costs continue to rise, states need to engage in strategies that include policy and nonpolicy options to manage prescription spending in Medicaid.

Regenerative and targeted therapies increase the need to accurately identify rare diseases, and increased specificity in diagnosis codes of the ICD-10 could help

This paper discusses several decision points and considerations for states evaluating a single preferred drug list requirement.

Insurers, policymakers, and government agencies in the United States may find it useful to have an accurate expectation for the length of enrollment by subscribers with a dependent who suffers from a pediatric rare disease and may be a candidate for a regenerative therapy with a potentially prolonged benefit.

This brief provides data on the decline in opioids prescribed to Medicaid expansion populations and the increased use of other non-opioid pain relief drugs.

Hemophilia, a bleeding disorder, is traditionally known as a condition affecting males. But it’s possible for females to have hemophilia. This paper discusses some reasons why hemophilia may go undiagnosed in women.